Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma

Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma

Abstract Background Despite the development of new treatment protocols for glioblastoma (GBM), temozolomide (TMZ) resistance remains a primary hindrance. Previous studies, including our study, have shown that aberrant N6‐methyladenosine (m6A) modification is implicated in GBM pathobiology. However,...

Full description

Bibliographic Details
Main Authors: Fuxi Li, Siyun Chen, Jiaming Yu, Zhuoxing Gao, Zhangyi Sun, Yang Yi, Teng Long, Chuanxia Zhang, Yuzhe Li, Yimin Pan, Chaoying Qin, Wenyong Long, Qing Liu, Wei Zhao
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Clinical and Translational Medicine
Subjects:
glioblastoma
histone modifications
m6A
METTL3
TMZ resistance
Online Access:https://doi.org/10.1002/ctm2.553

Internet

https://doi.org/10.1002/ctm2.553

Similar Items